Drug Shortages in Health Care Institutions: Perspectives in Early 2013
The year 2012 was perceived by many stakeholders as the worst ever with respect to drug shortages in Canada. Following receipt of a warning letter 1 from the US Food and Drug Administration in November 2011, Novartis International AG, on behalf of its Canadian operations at Sandoz Canada, issued a customer letter 2 in mid-February 2012 indicating that the company's production capacity would be significantly reduced for some time, that manufacturing would be suspended for many products, and that many other products would be available only in limited quantities through a national allocation process. Hospital pharmacists were active during the crisis in attempting to limit the impact of the resulting drug shortages. As a result of this crisis, unprecedented mobilization of stakeholders was observed throughout the country, and purchasing agents and professional organizations collaborated to form task forces at both the national and the provincial level. In addition, 2 bodies published key reports: in April 2012, the Ordre des pharmaciens du Québec (Quebec Society of Pharmacists) published a set of recommendations on interruptions in the drug supply, 3 and in June 2012, the House of Commons Standing Committee on Health published its own report on the Canadian drug supply. 6 Most of the drug shortages in 2011-2012 involved generic drug manufacturers, which represented 67% of the total number of drug shortages and 74% of the total number of drug-shortage days. The main manufacturers involved were, in decreasing order of proportion of total number of shortages, Teva (18%), Apotex (16%), Sandoz (14%), Hospira (8%), Pharmascience (6%), and Baxter (5%).
Most therapeutic classes were affected by shortages in 2011-2012. In decreasing order of the number of drug shortages, drug classes affected were central nervous system agents (AHFS drug classification 28:00), accounting for 22% of affected products; anti-infective agents (08:00), 14%; cardiovascular drugs (24:00), 14%; skin and mucous membrane agents (84:00), 8%; gastrointestinal drugs (56:00), 7%; hormones and synthetic substitutes (68:00), 7%; electrolytic, caloric, and water balance agents (40:00), 6%; antineoplastic drugs (10:00), 4%; and all other classes (18%).
This update indicates an important increase in drug shortages for the period from September 2011 to August 2012, with 4 generic drug manufacturers accounting for more than 50% of the total number of drug shortages. Although shortages of parental drugs represented only a third of all shortages, lack of supply of these drugs can have greater consequences (relative to other types of drugs) on patient safety in acute care and hospital settings, especially when multiple agents are produced by a single manufacturer.
In the southwestern region of Quebec, drug manufacturers have been expected to self-report shortages to the "Friday PM" website since late 2011. Although it would have been more accurate to use the manufacturer's self-reported data, we used only data from the wholesaler for the analysis reported above, because these data conform with the methodology that our research group has used since 2004. More specifically, we identified 42% under-reporting of drug shortages by the wholesaler relative to self-reporting by the manufacturers. This gap is largely explained by shortages reported by Apotex but not by the wholesaler. Such under-reporting by the wholesaler may be explained by the existence of sufficient inventory levels of some drugs, the availability of other formulations from one or more other generic drug manufacturers, and other in-house factors. Certainly, the situation in 2011-2012 was worse than what we have reported previously. 5, 6 Further analysis will be conducted in 2012-2013, using self-reported data from drug manufacturers, once a full year of such data are available.
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Strong action is required to encourage federal legislative changes and to reverse this negative trend in the Canadian pharmaceutical market. Meanwhile, we will continue to monitor the situation.
In Canada, the Food and Drug Act allows the distribution of drug samples to physicians, dentists, and pharmacists. 1 Most provincial regulatory authorities do not prohibit the distribution of such samples in health care settings. 2 However, drug samples are perceived differently by different health care stakeholders. 2 In particular, the use of drug samples may bypass the optimal druguse process in hospitals and retail pharmacies. [3] [4] [5] The objective of this cross-sectional observational study was to compare the number of drug samples available in outpatient clinics in a mother-child university hospital centre in the province of Quebec in 2007, 2009, and 2012. In the study hospital, drug samples were not allowed in patient wards but were tolerated in outpatient clinics. Drug samples were monitored every 6 months by pharmacy staff, who made unannounced visits to the clinics. In addition to biannual monitoring, extensive audits were conducted periodically over 1-to 2-week periods. During the first extensive audit, in 2007, the 
